Jiayi Huang¹, Xue Bai¹, Xiaofeng Xie¹, Liping Chen¹, Xiaofeng Lan¹, Qiuyi Zhang¹, Lin Song¹, Pengjiao Hong^2,3, Caiwen Du^1,*

Oncologie, Vol.24, No.1, pp. 131-145, 2022, DOI:10.32604/oncologie.2022.019881

Abstract Background: Vinorelbine can be used to treat metastatic breast cancer as a single agent or in combination with other chemotherapy agents, although there is little real-world data for its use, particularly the oral form, in China. The current study aimed to explore the efficacy and safety of oral vinorelbine in patients with metastatic breast cancer in real-world clinical practice. Methods: A total of 194 patients with metastatic breast cancer received oral vinorelbine as a treatment between February 2017 and January 2021 at the National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences… More >

LU YANG^1,#, YUN LIU^1,#, BOKE ZHANG², MENGSI YU³, FEN HUANG¹, YANG WEN¹, JIANGZHENG ZENG¹, YANDA LU¹, CHANGCHENG YANG¹

BIOCELL, Vol.46, No.5, pp. 1215-1243, 2022, DOI:10.32604/biocell.2022.018221

Abstract The aim of this study was to reveal genes associated with breast cancer metastasis, to investigate their intrinsic relationship with immune cell infiltration in the tumor microenvironment, and to screen for prognostic biomarkers. Gene expression data of breast cancer patients and their metastases were downloaded from the GEO, TCGA database. R language package was used to screen for differentially expressed genes, enrichment analysis of genes, PPI network construction, and also to elucidate key genes for diagnostic and prognostic survival. Spearman’s r correlation was used to analyze the correlation between key genes and infiltrating immune cells. We screened 25 hub genes,… More >

Keiichi Kontani^1,*, Kana Kuraishi¹, Shin-ichiro Hashimoto¹, Shoko Norimura², Nozomi Hashimoto¹, Masahiro Ohtani³, Naomi Fujiwara-Honjo⁴, Manabu Date⁵, Koji Teramoto⁶, Hiroyasu Yokomise¹

Oncologie, Vol.23, No.2, pp. 229-239, 2021, DOI:10.32604/Oncologie.2021.016277

Abstract The prognosis of patients with human epidermal growth factor receptor-2 (HER2)-overexpressed metastatic breast cancer (MBC) has improved drastically following the development of anti-HER2 therapies. We question what factors are involved in the improved outcome by the treatment. One hundred and two MBC patients who received chemotherapy were classified into groups according to breast cancer subtype: luminal/HER2-negative (n = 50), HER2 (n = 26), and triple-negative subtypes (n = 26). Clinicopathologic features and clinical outcomes of the groups were compared. Disease-free intervals in the triple-negative group were significantly shorter than those in the other two groups. Age, tumor grade, the number… More >